Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
All 8 EUA's are clearly possible. But what if only 5 or 6 are successful ? I wouldn't short Sorrento ...but I'm glad others are. It will only benefit the longs!
Over the next few weeks and months I see 8 EUA's.
1. Covi-Stix rapid accurate virus test
2. Covi-Track rapid accurate antibody test
3. Covi-push 2020 injection
4. Covi-Drops 2020 nose drops
5. Covi-Vax 2020 lipid DNA injection($34 million DARPA funding)
6. Abivirtinib ARDS prevention
7. Covi-MSC Stem Cell ARDS treatment
8. Covi-Shield antibody cocktail(2020 plus variants)
Each and every one has a blockbuster sales potential. Dr. Ji says the marketing arrangements are ready to go! And watch for Abivertinib in cancer, the first Dar-T, second generation oncolytic virus and SP-102 news.
People will learn to listen to what Dr. Ji is saying. He cannot be expected to change the sort of nonsensical delays that small biotechs must overcome while the big boys move ahead(Abbott tests were garbage). But he is a brilliant scientist with an amazing record of outstanding acquisitions. There's a lot of great news coming over the next few weeks and months! I originally bought for the cancer and non-opioid pain programs. However many of the Covid programs will soon be receiving EUA's. I've never been more confident of an investment. The shorters simply have no grounds to criticize the brilliant science and powerful financial status!
.
ANOTHER NEW PATENT APPLICATION!
United States Patent Application 20210017274
Kind Code A1
Miao; Zhenwei ; et al. January 21, 2021
Drug-Conjugates With a Targeting Molecule and Two Different Drugs
Abstract
There is disclosed an improved ADC (antibody drug conjugate) type composition having at least two different drug payloads conjugated to a single targeting protein. More specifically, the present disclosure attaches a first drug conjugate to a dual Cysteine residue on a targeting protein and a second drug conjugate with a different drug to a Lys residue on the targeting protein.
I can't find a cancer program more exciting than Sorrento's. Abivirtinib, at least 12 ADNAB's, DAR-T, Vacci-body targeting cancer, 20 potential ADC's.
I can't find an non-opioid pain program more exciting than Sorrento's. SP-102 and RTX are each potential 5-6 billion dollar earners.
I can't find a Covid program with greater potential than Sorrento's. 8 potential EUA's, inexpensive highly accurate tests, powerful Mabs, Vacci-bodies targeting Covid, Abivertinib to prevent cytokine storm, Covi-MSC to rescue from ARDS.
I'm loaded and ready for the news over the next few days, weeks and months. IMO 2021 will be the inflection point for Sorrento!
Chuck does some interesting analysis on SP-102 potential.
"Think about forward looking revenue / earning and how that impacts valuation. Typically, for this segment, SP value is typically estimated based on 9 to 11 times revenue or 22 to 24 times earnings with typical revenue contribution of over 40% margin to ebitda.
At $5 to $6 billion potential REVENUE for SP-102 that means Valuation at $50 billion for SRNE based on this product. If we use 280 million shares to estimate SP, we have a SP of $178. This takes the value over Ji’s threshold so he would get his full comp package on a BO at this value. For any offer of BO, the purchaser would need to offer a premium of at least 50% over valuation estimate. This would put a post SP-102 BO offer in the $400 dollar range which would be ok by me."
Robert posted this helpful information. Could be significant!
"I just noticed the COVI-STIX page on the Sorrento website has been updated. Not sure if this has already been mentioned or when exactly this update took place. However a little research on the internet wayback machine shows that the update took place some time between March 3rd and today. March 2nd is the last available archive or snapshot on the wayback machine for Sorrento's website.
They updated the page with a new COVI-STIX depiction showing step by step intructions on how to use the test. Why is this significant? The FDA states that these instructions must be listed on the manufacturers website prior to issuing an EUA.
Here are the links to the March 2nd archive of Sorrento's website and todays current link.
https://web.archive.org/web/20210127093619/https://sorrentotherapeutics.com/research/covid-19/covi-stix/
https://sorrentotherapeutics.com/research/covid-19/covistix/
ST...you are on a roll today. All is good!
Great portfolio. Great financial position. Genius CEO!
When the big boys are loaded up...up she goes.
They'll make more money taking it up to $300-400 than lending out their shares. The 2,000 pound gorilla that's holding the share price down will get behind the share price increase...and us little retail investors get to go along for the ride! I seen this happen many times.
YES Sorrento had 12 IND's in 2020 and it looks like at least 14 more are coming in 2021. So where is the money coming from to advance the pipeline?
I agree with those who see COVI-STIX and COVI-MSC as EUA candidates and possible revenue earners reasonably soon. But we should recall that there are 6 more potential EUA candidates lined up behind them. That's a lot of potential revenue and partnerships!
But any time Sorrento needs cash they can sell their shares in IBRX for $300+ million and/or their shares in Celularity for $400+ million. And most observers agree that PSS will be handing over some $1.2 Billion in a few months.
And next year there will be billions in revenue from SP-102, RTX and possibly Abivirtinib in cancer and cytokine storm.
Do I worry that Sorrento needs cash? NO.
Do I expect Sorrento will receive some some unsolicited buyout offers? YES.
In ships, tanks and aircraft crews often can't social distance or mask! I expect ANOTHER DARPA grant will come soon!
DARPA should be interested is accelerating approval of the new multi-strain vaxi-body. They need to protect the military who are exposed to worldwide variants of Covid!
San Diego company creating stronger antibody that fights all coronavirus variants. It's a partnership with Mount Sanai.
By: Leah PezzettiPosted at 5:20 PM, Mar 09, 2021
SAN DIEGO, Calif. (KGTV) - San Diego-based company Sorrento Therapeutics and Mount Sinai are collaborating on the further development of monoclonal antibodies for therapeutic applications.
The antibodies should be able to fight any variant of coronavirus.
Sorrento currently has treatments undergoing clinical trials that can be given in two different ways. The first way is through an IV, a process that takes 2-3 minutes. The second way is through drops in the nose, which ideally will be a simple tactic to use if a person tests positive.
“You go to CVS, pick it up, put a few drops in your nose and prevent the virus from replicating, gets injected into the lung and preventing you from spreading the virus,” said Henry Ji, Chairman and CEO of Sorrento Therapeutics.
He said the antibody they have created is more potent, meaning they can make more doses. This will create more access to protection against the virus. It is also expected to only cost a few hundred dollars, which is a cheaper alternative than spending tens of thousands for an infusion in a hospital.
“So for the average person, it gives them hope, getting a diagnosis of COVID, if they haven’t been vaccinated or the vaccine did take, they now have additional options to prevent anything serious from happened,” said Mark Brunswick, Senior Vice President for Regulatory Affairs and Quality.
Ji said the part of their antibody that they’re most excited about is the fact that they believe it should fight against all known strains of the virus, including the UK strain, the South African strain, and the Japan/Brazil strain.
Their “vaxi-body,” which is a vaccine antibody, should not only treat people who have tested positive but also protect against any future exposures, similar to what current vaccines are doing. That prevention paired with the protection against all known strain is important moving forward as other variants have the possibility of becoming more prevalent, and also people need follow-up doses in the future.
“It’s definitely not a one-and-done vaccine and if this virus keeps on mutating, escaping all of the immunity you established, it’s going to be multi-years. That’s why the whole world, scientists are working on this to solve the problem,” said Ji.
Sorrento is currently putting these antibodies through trials with healthy volunteers and hopes to complete the trials by the end of 2021.
Why is COVI-SHIELD needed? This is from today's Business Insider:
"COVID-19 vaccines from Moderna and Pfizer-BioNTech appear significantly less effective against the coronavirus variant first found in South Africa, a lab study has suggested.
The percentage of protective antibodies that neutralized the variant - called B.1.351, which has been recorded in 20 US states - was 12.4 times lower for Moderna's COVID-19 shot than against the original coronavirus, and 10.3 times lower for Pfizer's, the study authors said.
This was a bigger drop than in previous lab studies testing the vaccines against manufactured forms of the variant, they said. For this study, the researchers used real forms of the variant taken from people who had caught the virus."
COVISHIELD, which is under development, will be a combination of two monoclonal antibodies designed to protect against disease caused by existing and emerging variants of SARS-CoV-2. Using the early pandemic variants as well as the emerging variants of concern (“VOCs”) that have increased in prevalence globally through the course of the pandemic, Sorrento identified candidate monoclonal antibody combinations, or “cocktails”, with potent activity against the breadth of these VOCs, including the United Kingdom (B.1.1.7), South Africa (B.1.351), and Japan/Brazil (B.1.128) variants. Positive results from these laboratory studies are expected to support the future research path and FDA evaluation of COVISHIELD.
Some interesting information on the SOFUSA lymphatic delivery system.
https://www.researchgate.net/figure/a-The-SOFUSA-nanotopographical-device-i-Microfluidic-fluid-block-with-a-perforated_fig1_317351779
More coming from the Lee partnership!
"Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics, stated, “We at Sorrento are happy with the collaboration with our colleagues at Lee’s Pharma and are satisfied with the clinical advance of our first therapeutic antibody partnership in socazolimab. We currently plan to expand our partnership with Lee’s Pharma and are in discussions regarding the co-development of additional therapeutic antibodies from Sorrento to treat hematologic and solid tumors.”
The anti-PD-L1 is obviously another blockbuster drug. It can bring in hundreds of millions of upfront, milestone and royalty payments. Or simply be sold off for billions to finance the rest of the cancer pipline eg. ADNAB, DAR-T and plasmid DNA!
The anti-PD-L1 antibody has many combination applications in cervical, osteosarcoma, urothelial, small cell lung, and esophageal cancer indications! Sorrento will receive milestone and royalty payments from China and has full rights in ROW. Apparently it moved straight from a phase 1b to a phase III trial in SCLC. Very impressive!
Lee’s Pharmaceutical Announces its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Clearance to Start Phase 3 Trial as a First-line Treatment of Extensive-stage Small-Cell Lung Cancer
March 7, 2021 at 10:27 PM EST
Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lee’s Pharm.
China’s National Medical Products Administration (“NMPA”) clears Lee’s Pharm to conduct a Phase III, multicenter, randomized, double blinded, parallel-group clinical trial of Socazolimab (anti-PD-L1 monoclonal antibody, formerly known as ZKAB001) combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.
SAN DIEGO, March 07, 2021 (GLOBE NEWSWIRE) -- China Oncology Focus Limited (COF), an affiliate of Lee's Pharmaceutical Holdings Limited (Lee's Pharm, HKEX: 950) announced that its anti-PD-L1 antibody, Socazolimab, licensed from Sorrento to COF for the greater China territory, has been cleared to begin a multicenter, randomized, double blinded, parallel-group clinical trial of Socazolimab (anti-PD-L1 monoclonal antibody, formerly known as ZKAB001) combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer. The clearance is based on the results from an earlier Phase Ib trial in which Socazolimab combined with carboplatin and etoposide showed a promising efficacy and safety profile in patients with extensive-stage small-cell lung cancer. The Principal Investigator for the clinical trial will be Professor Shun Lu from the Shanghai Chest Hospital and the site is expected to initiate patient recruitment in the second quarter of 2021.
Socazolimab is an in-licensed product from Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) for the People’s Republic of China, Hong Kong, Macau and Taiwan. Three Phase I clinical trials of Socazolimab monotherapy have been completed: (1) recurrent or metastatic cervical cancer; (2) advanced urothelial carcinoma; and (3) high-grade osteosarcoma after adjuvant chemotherapy for maintenance purposes. For recurrent or metastatic cervical cancer, a pivotal study has been completed and breakthrough therapy designation was granted by the NMPA in February 2021. Lee’s Pharm expects to file the New Drug Application for Socazolimab in recurrent or metastatic cervical cancer in the second quarter of 2021. Apart from monotherapies, several studies of Socazolimab combining with chemotherapy are being conducted in advanced urothelial carcinoma (Phase Ib), extensive-stage small-cell lung cancer (Phase III), and neoadjuvant treatment in esophageal carcinoma (Phase Ib+II).
Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics, stated, “We at Sorrento are pleased with the collaboration with our colleagues at Lee’s Pharm and with the further advances of our first therapeutic antibody partnership in Socazolimab.”
About Socazolimab
Socazolimab is a fully human anti-PD-L1 monoclonal antibody identified by Sorrento using its proprietary G-MAB™ library platform. COF received exclusive rights to develop and commercialize the antibody for Greater China, which includes Mainland China, Hong Kong, Macau, and Taiwan. Socazolimab has the following potential advantages over its competitors:
Fully human antibody potentially allows it to have minimal immunogenicity; demonstrated by its negative antigen-derived antibody (ADA) generation in humans in studies to date.
Potentially lower dose required to achieve efficacy compared to other anti-PD-L1 antibodies.
Dual mechanism of action observed with both immune-checkpoint inhibition and antibody-dependent cellular cytotoxicity (ADCC) effect.
The antibody has been tested or is being tested in various cancer indications including recurrent or metastatic cervical cancer, maintenance therapy for high-grade osteosarcoma after adjuvant chemotherapy, locally advanced and metastatic urothelial carcinoma, extensive small cell lung cancer in combination with carboplatin and etoposide, and advanced urothelial carcinoma in combination with albumin-bound paclitaxel and esophageal carcinoma.
US population 330 million. World population 7.7 billion. And viruses, cancer and pain will be with us until NHNE.
The entire biotech sector has been pounded. What Sorrento needs are one or two approvals! I expect at least two this month.
* EUA granted for Covi-Stix
* EUA granted for Covi-Track
* These approvals will be followed by worldwide sales partnerships.
* We should also hear from the interim analysis of the Abivirtinib phase 2 trial to prevent cytokine storm. Will this also receive an EUA? If so we should also expect approvals and sales around the world beginning in the US, Mexico and Brazil.
* I also expect good results will be announced from the open label phase 1 Covi-MSC trial of 20 patients with ARDS. And a pivotal phase 2 trial will begin.
And there should be more good news from the cancer and pain portfolios in the next month or two. The great science will prevail!
For discussion I'm reposting @ScottG's very interesting comments on COVIDROPS and, by implication, Sorrento's whole COVID pipeline:
"I'm not sure you need scientific/medical knowledge to have a decent opinion on this, except for one or two use cases. Let's consider...
* If you didn't get a vaccine, for whatever reason, and end up getting COVID, you're going to want a treatment, of which there are several. However, as yet there's no good solid early stage treatments that are considered high probability successful options. We've seen a variety of drugs used at several stages that seem to have had at least some positive outcomes, but they require high dosages, typically delivered via IV, and are expensive. If a couple of nasal drops are proven to truly be effective, that's an easy choice for any doctor.
* If you got a vaccine, but still get COVID and it seems to be progressing past mild or even if it's mild and doesn't go away in a few days, then you're also headed for a therapeutic 'cure' if you can get one.
* Let's look a the whole world for a moment... Across the Rich World, (however you choose to define that), anyone who wants a vaccine will probably have one within the next 12 month; give or take a couple of months either way. And those shots will last... well... we don't know. So, (leaving aside the anti vax folks who don't get a shot), meanwhile, BILLIONS in the poor countries will still be at risk. Which means, they keep passing it around and when immunity for others wears off, this thing comes roaring back. So, assuming it will take several more years to dose the billions of poor in poorer countries, to knock this thing down and avoid resurgence, when outbreaks happen the ability to knock it out quickly will be key. Regardless what anyone thinks about foreign aid, it's in the world's best interest to pay for a C-130 or whatever full of Covi-drops to set up wherever this thing bursts out and try to knock it down.
* Next, your vaccinated. It's 1.5 - 2 years later. Studies come to show - for as yet unknown reasons - 30% of people are no longer sporting effective immunity. They'll need therapeutics. (And so yeah, testing will be needed - likely at decent scale - for years; perhaps a decade or more, until or unless we can effectively eradicate. Which we've done before, as with smallpox. But it takes a worldwide effort.)
Briefly, this drug is desperately needed NOW, regardless of having even effective vaccines and will be useful for a long time. The market for it might not be as massive as if we had no vaccines. But it's still there. Moreover, it's one incredible endorsement for the company that understands the disease well enough to produce multiple solutions.
One Wildcard: If vaccines, (or some of them anyway), don't work against some variants, but this does, then it becomes one of the most important drugs of our modern times.
I'm sure I'm missing some use cases. But there you go."
I am glad Sorrento is testing its drugs in Brazil." Brazil's hospitals reach breaking point as health minister blames new coronavirus variants."
https://www.cnn.com/2021/03/01/americas/brazil-hospitals-coronavirus-variants-blame-intl-latam/index.html
It's STI-2020...a monoclonal antibody.
That spray only attempts to "reduce the symptoms". Covi-Drops attacks the virus. At the present time Sorrento leads the pack!
You become what you worship. Worship your golden idol who Cruz described as a pathological liar all you like.
But it's OK when a pathetic loser uses his FOX megaphone to falsely claim the election was stolen and fires up his right wing Proud Boys, QAnon and KKK supporters to storm the Congress, wound 100 police officers and cause the death of 5 or 6 people. They would have hung Pence if they caught him. Too bad John McCain is not around to straighten out his former colleagues.
The FIRST nose drops! Expect a rapid phase 1 followed by a phase 2 aimed to receive an EUA. You have to admire the Sorrento Covid pipeline. Early treatment(Drops), later treatment(push-injection),ARDS prevention(Abivirtinib), ARDS rescue(Covi-MSC)and a treatment for Covid long-haulers. And the next could be the plasmid DNA Vacci-body! These are all aiming for rapid EUA approvals...and several are already in potentially pivotal phase 2.
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Study for STI-2099 (Intranasal COVIDROPS) in Healthy Volunteers and Outpatient Treatment for Newly Diagnosed COVID-19 Positive Patients
March 2, 2021 at 4:02 PM EST
FDA granted IND clearance today for the commencement of a Phase 1 safety and pharmacokinetic study for STI-2099 (COVIDROPS™) in healthy volunteers and outpatients with mild COVID-19 disease with or without a simultaneous intravenous injection of STI-2020 (COVI-AMG™).
Initial trials are expected to be followed by a Phase 2 trial in both mild and moderate COVID-19 patients, either as a stand-alone nasal application or as a combination nasal and intravenous administration.
This is the first FDA clearance of a clinical trial of intranasal administration of a neutralizing antibody against the SARS-CoV-2 virus.
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it has received clearance from the FDA for its Investigational New Drug application (IND) for its Phase 1 study of the safety and pharmacokinetics of intranasal (IN) STI-2099 (COVIDROPS) in both healthy volunteers and patients with mild COVID-19.
As previously announced, Sorrento is currently evaluating an intravenous formulation of this potent antibody, STI-2020 (IV), in a Phase 1 study in healthy volunteers and COVID-19 patients with mild symptoms. This small volume IV-push formulation is being tested against the dominant strain of the SARS-CoV-2 virus in the U.S. as well as the emerging UK variant. Sorrento expects to evaluate STI-2099 (IN) alone or in combination with STI-2020 (IV) to treat newly diagnosed patients.
Treatment with STI-2099 has the potential to halt the COVID-19 infection at the earliest stage in the nasal passages before it has a chance to spread to the lungs, and, if the infection has already hit the lungs, prevent the development of severe infections. If found to be safe and effective following clinical trials, STI-2099 i has the potential to prevent hospitalization or discharge hospitalized COVID-19 patients faster. “We plan to use our intranasal formulation technology, which allows administering a drug via simple drops in the nose, for other antibodies we are currently developing with a goal of providing coverage against all variants of the SARS-CoV-2 virus that might evade inhibition from treatment with existing therapies,” said Dr. Henry Ji, Chairman and CEO of Sorrento.
About Sorrento Therapeutics, Inc.
Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”, “DAR-T™”), antibody-drug conjugates (“ADCs”), and clinical stage oncolytic virus (“Seprehvir™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIGUARD™, COVI-AMG™, COVISHIELD™, Gene-MAb™, COVI-MSC™ and COVIDROPS™; and diagnostic test solutions, including COVITRACK™, COVISTIX™ and COVITRACE™.
Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido® was approved by the FDA on February 28, 2018.
For more information visit www.sorrentotherapeutics.com
He doesn't hate himself. He hates bigotry which goes back to slavery and segregation...and which white supremacists spout today.
If attacking people like Brennan who have honorably served their country works for you good luck with that.
My ancestry is Irish, Scots and Viking...but I too am ashamed of White bigotry in America...good grief indeed!
Potential to be "best-in-class"
"In preclinical evaluations, STI-6643 displayed decreased red blood cell binding and hemolysis, while maintaining potent anti-tumor activity in solid tumor disease models. Clinical trials with anti-CD47 mAbs have historically experienced limitations due to significant anemia, hemagglutination, and thrombocytopenia due to CD47 expression on normal red blood cells, ultimately requiring employment of complicated clinical dosing regimens. These issues have not been seen to date with STI-6643 in preclinical studies conducted head-to-head against synthesized versions of other CD47 mAbs. Additionally, STI-6643 showed minimal T, B or NK cell depletion as opposed to other synthesized mAb clones, which could potentially result in improved efficacy by preserving infiltrating anti-tumor immune cells. STI-6643 has the potential to be a “best-in-class” product if these preclinical benefits are able to be reproduced in human trials. Sorrento is also conducting preclinical studies to compare the safety and efficacy of lymphatic delivery of STI-6643 to established parenteral routes of administration using Sorrento’s Sofusa™ technology."
It would be great to see Sorrento tackle malaria and many other tropical diseases. Big Pharma ignored them because the tropics are largely inhabited by poor people...and it is hard to make megabucks from treating these diseases. I believe Dr. Ji is a man of high principles and very well might take on the battle against Ebola, malaria, Dengue etc. Sorrento is amassing an amazing combination of leading edge technologies. I know the military who serve in these areas would likely fund the research. DARPA connections are already in place!
Can you image the application of this ANP technology to Sorrento's antibodies!
"Nanoencapsulation of Protein/Antibody Drugs
ANP-015 is a nanoencapsulated antibody cocktail for the treatment of Zaire Ebola virus. The naked antibody cocktail is currently the most effectivetreatment for Ebola infection under compassionate use. However, it can only be shipped and stored at -80 °C, which makes it very difficult to use in low resource areas such as West Africa. Through the utilization of our nano-drug delivery system, our nanoencapsulated antibody cocktail can be shipped and stored at room or elevated temperatures. Importantly, this technology can be applied to other large molecule based therapeutics that need better stability across a broad temperature range.
Recently, ANP Technologies®, Inc.. is working on the development and clinical testing of ANP-015. As mentioned above, this new, highly effective, and temperature stable antibody therapy for the treatment of Ebola infection will help save countless lives through its drastically improved stability.
Advantages:
Significantly improved stability of large molecule therapeutic proteins to allow storage at room temperature or above.
Identical efficacy to non-encapsulated antibody even after exposed to extreme heat conditions, as demonstrated by both in vitro and in vivo studies."
I agree. On the Riley interview Dr.Ji said "My goal is to build the company in the next three to five years into a $200 billion company." I take what he says seriously. I consider him to be a brilliant scientist with excellent business acumen! A rare combination.
2 important deals in one day! Just look at his Celularity, ImmunityBio, ADNAB(Mayo Clinic) and SmartPharm deals.
Behind it all are 2 clear facts.
1. Dr. Ji knows what he is doing!
2. Sorrento has LOTS OF CASH AND ASSETS!
1776...Just one successful cancer drug can net them several 100 million dollars each year for many years. And the testing strength of this acquisition may be the underlying reason. Dr. Ji may tell us more the next time that he does a Riley type "fireside chat"!
Is Sorrento getting closer to DARPA?
"ANP Technologies®, Inc., originally spun out from the U.S. Army Research Laboratory in 2002, is an innovation-driven company which has successfully developed multiple product platforms based on proprietary/patented nanobiomaterials and the nanoscale manipulation of their spatial orientation. We have focused the application of our technologies, known as the Nano-Intelligent Detection/Delivery System (NIDS®), on the following major areas of application:
Drug Delivery
Encapsulation of poorly soluble drugs in nanoparticles using our library of polymers improves their solubility and therapeutic outcomes. We have coined the term “nanoencapsulation” to describe our polymer technology’s ability to increase the safety and efficacy of poorly-soluble and highly cytotoxic compounds in the treatment of various diseases and pathologies. In collaboration with our partners, various nanoencapsulated poorly soluble drugs for IV injection have been developed for the treatment of lung, breast, ovarian, pancreatic cancers, as well as CNS related diseases.
Rapid Detection of Biowarfare Agents
ANP has developed rapid lateral-flow immunoassays currently fielded by the US Department of Defense and Department of Homeland Security for the detection of biowarfare/biothreat agents. By employing nanomanipulation techniques, our NIDS® assay is the only handheld assay that does not suffer from the deadly false negative high-dose hook effect that has plagued all the other handheld assays on the market. Additional multiplexed detection capability along with the use of a handheld reader that completely eliminates human to human reading and environmental lighting variations has made the NIDS® rapid assays the top choice for military, state and local first responders."
Note that the top 3 technologies are being advanced using 505(b)2...
"The 505(b)(2) is a New Drug Application (NDA) mechanism which allows an applicant to seek approval for a drug product based on full safety and efficacy documentation, some of which may be from literature or conducted by others and for which the applicant does not have the right of reference.
Created in 1984, it is a streamlined process and does not require the applicant to conduct all the required studies or obtain a right of reference.
A 505(b)(2) can been used to get approvals for changes such as New Delivery Mechanisms, New Dosage Forms, New Formulations and New Indications. It has the advantage over the traditional process by being able to rely on previously published material, and so can be quicker as well as being lower cost"